MHRA-initiated safety actions
MHRA's enforcement powers derive from the UK MDR 2002 (SI 2002/618 as amended) and the Medicines and Healthcare products Regulatory Agency Act framework. MHRA acts as market surveillance authority and has broad powers to require action or act independently.
MHRA's role in post-market safety
MHRA is not only a recipient of manufacturer vigilance reports — it is an active post-market surveillance authority with independent powers to investigate and act on device safety concerns.
MHRA may become aware of safety issues through:
- Vigilance reports from manufacturers
- Yellow Card reports from healthcare professionals and patients
- Market surveillance activities (testing devices purchased on the market)
- Information from other regulators (EU, FDA, TGA, Health Canada)
- Media and social media monitoring
- Direct reports from healthcare facilities
MHRA-initiated safety actions
1. Requests for information
MHRA can require a manufacturer or UKRP to provide:
- Technical files and declarations of conformity
- Post-market surveillance data
- Complaint records and investigation reports
- Batch/lot information and distribution records
Failure to provide information on request is a violation of UK MDR 2002 obligations.
2. Enforcement notices
Where MHRA identifies a non-compliance, it can issue an enforcement notice requiring the manufacturer/UKRP to take specific corrective action within a defined timeframe.
3. Prohibition notices
MHRA can prohibit the further supply of a specific device where it presents an unacceptable risk. A prohibition notice prevents the device from being placed on the GB market or put into service.
4. Recall orders
MHRA can order a recall of devices already on the market or in use if MHRA determines there is a serious risk and the manufacturer has not acted adequately.
5. Public warnings
MHRA publishes public warnings and Device Alerts on the gov.uk website when there is a safety issue that healthcare professionals or patients need to be aware of urgently. These are published without waiting for manufacturer action if the risk is immediate.
6. Criminal prosecution
In cases of serious, deliberate, or repeated non-compliance, MHRA can bring criminal proceedings against manufacturers, UKRPs, or responsible individuals under the UK MDR 2002.
Responding to MHRA-initiated actions
When MHRA contacts a manufacturer about a potential safety issue:
- Respond promptly and completely to information requests
- Engage constructively — MHRA's goal is patient protection, not punishment
- Document all communications with MHRA
- Seek legal advice if criminal action is threatened
A manufacturer's cooperative response to MHRA concerns significantly affects the regulatory outcome.
Official references
| Reference | Description |
|---|---|
| UK MDR 2002, Regulations 16–22, Part 7 | Enforcement powers |
| MHRA: Enforcement strategy | MHRA's published enforcement approach |
| MHRA: Device alerts | gov.uk/drug-device-alerts |